ArticleFuture oncology (London, England)2025

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

Kenneth O'Byrne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.